Sargramostim
Sargramostim is a highly purified glycosylated protein consisting of 127 a.a,produced by recombinant DNA synthesis in yeast culture.It stimulates production of WBC.
Primary Characteristics
Non-proprietary name: Sargramostim.
Pharmacokinetics
Elimination: plasma half-life is 162 min.
Advertisement
Indications
Sargramostim is primarily indicated in conditions like Acute myeloid leukemia, Bone marrow transplantation.
Sargramostim is also indicated for secondary conditions like Infections, Neutropenia.
Contraindications
Sargramostim is contraindicated in conditions like Myeloblastic leukemia, Hypersensitivity.
Dosage
Sargramostim's dosage details are as follows:
| Dose | Single Dose | Frequency | Route | Instructions |
|---|---|---|---|---|
| Adult Dosage | ||||
| 250 mcg/m² | 250 mcg/m² | — | IV Infusion | |
| Paediatric Dosage (20kg) | ||||
| No data. | ||||
| Neonatal Dosage (3kg) | ||||
| No data. | ||||
Drug Interactions
Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Side Effects
Sargramostim in overdosage may give rise to further complications which include Dizziness , Chest pain , Weight gain , Allergic reactions .
The signs and symptoms that are produced after acute overdosage of Sargramostim are Rashes , Nausea, Shortness of breadth, Fever.
Sargramostim is known to cause more or less tolerable side effects which are usually transient. These include Bone pain, Diarrhea, Loss of appetite, Muscle aching.
Warnings / Precautions
Available Brands
None recorded.